Senseonics Revenue and Competitors

Claim your profile

Location

$455.5M

Total Funding

Estimated Revenue & Valuation

  • Senseonics's estimated annual revenue is currently $36.1M per year.(i)
  • Senseonics received $149.5M in venture funding in July 2018.
  • Senseonics's estimated revenue per employee is $251,000
  • Senseonics's total funding is $455.5M.

Employee Data

  • Senseonics has 144 Employees.(i)
  • Senseonics grew their employee count by 7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2320M55009%$413.7M$43.4B

Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life. The system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

keywords:Biotechnology,Hardware,Healthcare,Medical Devices,Pharmaceuticals

$455.5M

Total Funding

144

Number of Employees

$36.1M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Senseonics News

2022-04-20 - Zacks: Analysts Anticipate Senseonics Holdings, Inc. (NYSE:SENS ...

Zacks: Analysts Anticipate Senseonics Holdings, Inc. (NYSE:SENS) Will Announce Quarterly Sales of $2.14 Million. Posted by admin on Apr 23rd,...

2022-04-06 - Senseonics Announces the First Patient Implant of the Eversense E3 ...

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed...

2022-04-06 - Senseonics Launches Eversense, but Is Dexcom's G7 Far Behind?

Senseonics Holdings has launched the Eversense E3 continuous glucose monitoring and has announced the first commercial implant of the device.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.7M1526%N/A
#2
$24.4M1539%N/A
#3
$45.7M1545%N/A
#4
$27M1745%N/A
#5
$40.7M176N/AN/A

Senseonics Funding

DateAmountRoundLead InvestorsReference
2002-04-19$30.0MCArticle
2005-11-04$UndisclosedUndisclosedMultipleArticle
2011-11-02$54.0MDDelphi VenturesArticle
2014-06-09$20.0MUndisclosedMultipleArticle
2014-08-20$10.0MUndisclosedOxford Finance LLCArticle
2015-08-14$10.0MUndisclosedArticle
2016-07-08$30.0MUndisclosedOxford Finance LLCArticle
2017-05-29$41.0MUndisclosedLeerink Partners LLCArticle
2017-08-21$28.8MUndisclosedNational Securities CorporationArticle
2018-01-29$55.3MUndisclosedBTIGArticle
2018-07-03$149.5MUndisclosedArticle